Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
NICE International has helped Egypt take a crucial step towards a fairer, more efficient healthcare system.
An end of year summary from our chief executive, Dr Sam Roberts.
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
Dr Sam Roberts, NICE's chief executive, welcomes the government's 10 Year Health Plan, which marks a pivotal moment for healthcare and strengthens NICE’s role.